Dirk T. Waldschmidt

Kerpener Str. 62
Koeln, NW 50937, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Early C-reactive protein kinetics predict outcomes in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors: a multicenter, observational study comparing different C-reactive protein kinetic definitions.

Early C-reactive protein kinetics predict outcomes in unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors: a multicenter, observational study comparing different C-reactive protein kinetic definitions.

Journal: Frontiers in oncology

Published: June 02, 2026

Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 08, 2026

Acute Upper Gastrointestinal Bleeding is Associated With Poor Prognosis in Patients With Biliary Tract Cancer.

Acute Upper Gastrointestinal Bleeding is Associated With Poor Prognosis in Patients With Biliary Tract Cancer.

Journal: Cancer medicine

Published: November 06, 2025

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).

Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).

Journal: BMJ open

Published: September 10, 2025

Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 13, 2025

Clinical Benefit of Structured Reporting Using the Liver Imaging Reporting and Data System (LI-RADS) in MRI in Patients at Risk for Hepatocellular Carcinoma.

Clinical Benefit of Structured Reporting Using the Liver Imaging Reporting and Data System (LI-RADS) in MRI in Patients at Risk for Hepatocellular Carcinoma.

Journal: RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin

Published: April 25, 2025

Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).

Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).

Journal: British journal of cancer

Published: March 24, 2025

A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.

A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma.

Journal: Hepatology (Baltimore, Md.)

Published: March 14, 2025

Resistance training in cachectic pancreatic and lung cancer patients: randomised controlled trial.

Resistance training in cachectic pancreatic and lung cancer patients: randomised controlled trial.

Journal: BMJ supportive & palliative care

Published: March 12, 2025

Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552].

Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552].

Journal: ESMO open

Published: October 26, 2024

Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).

Nanoliposomal Irinotecan With Fluorouracil and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Cholangiocarcinoma: A Phase II Study of the AIO Hepatobiliary-YMO Cancer Groups (NIFE-AIO-YMO HEP-0315).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 06, 2024

Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552].

Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552].

Journal: ESMO open

Published: May 04, 2024

Showing 1-12 of 45

Last Updated: 09/26/2026